Table 4.
Impact of NSAIDs on agreement between CE and US synovitis, excluding metatarsophalangeal joints and ankles*
| Clinical assessment | US synovitis assessment, GS ≥2 or PD ≥1 | |
|---|---|---|
| No NSAIDs | NSAIDs | |
| Tender and/or swollen joint | ||
| PEA | 72 (348/486) | 76 (612/808) |
| Sp0 | 82 (628/766) | 84 (994/1,190) |
| Sp1 | 33 (68/206) | 54 (230/426) |
| US > CE | 11 (54/486) | 9 (76/808) |
| US < CE | 17 (84/486) | 15 (120/808) |
| κ (95% CI) | 0.15 (0.05–0.25) | 0.38 (0.31–0.45) |
| PABAK | 0.44 | 0.52 |
*
Values are the percentage (number/total) unless indicated otherwise. NSAIDs = nonsteroidal antiinflammatory drugs; CE = clinical examination; US = ultrasound; GS = gray-scale; PD = power Doppler; PEA = percentage exact agreement; Sp0 = agreement specific to a score of 0; Sp1 = agreement specific to a score of 1; 95% CI = 95% confidence interval; PABAK = prevalence-adjusted bias-adjusted kappa.